Clinical Trial Update: Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

View source ↗

Summary

A clinical trial evaluating the PARP inhibitor olaparib for castration-resistant prostate cancer, including patients with BRCA mutations; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: Santa Chiara Hospital | Conditions: Prostate Cancer, Castrate Resistant Prostate Cancer | Status: RECRUITING